Tecvayli market seen growing on multiple myeloma demand and research spending

The Business Research Company says the global Tecvayli market is set for steady growth through 2035, driven by rising multiple myeloma cases, broader use of targeted therapies and heavier investment in cancer research. North America held the largest regional share in 2025, while the report highlights bispecific antibodies, BCMA-targeted treatments and combination therapy as key trends.

Why it matters: - Tecvayli sits in a growing oncology niche tied to relapsed or refractory multiple myeloma, a hard-to-treat blood cancer. - The market’s growth outlook reflects wider demand for targeted immunotherapies and more advanced late-line treatment options. - The report points to a longer-term opportunity through 2035 as providers and researchers push for better outcomes in difficult cases.

What happened: - The Business Research Company released a Tecvayli market report covering market size, trends and a global forecast for 2026-2035. - The report says the Tecvayli market grew historically on the back of better understanding of multiple myeloma, more biologic drug development, wider access to specialized oncology clinics and regulatory approvals for new immunotherapies. - The report projects continued expansion driven by next-generation immuno-oncology pipelines, personalized cancer therapies, more hematologic malignancy research, greater use of real-world evidence and broader access to advanced biologics in emerging regions. - The report highlights bispecific antibody therapies, BCMA-targeted treatments, combination therapy, late-line multiple myeloma care and patient monitoring during immunotherapy as major trends. - A free sample of the report is available here. - The full report is available here.

The details: - Tecvayli, or teclistamab, is used in adults with relapsed or refractory multiple myeloma. - Multiple myeloma is a cancer of plasma cells and is especially difficult to treat after patients have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug and an anti-CD38 monoclonal antibody. - Tecvayli works by boosting T-cell activity to target and destroy myeloma cells. - The report says rising multiple myeloma prevalence is a key growth driver for the market. - Aging populations and improved diagnosis are increasing demand for therapies such as Tecvayli. - The American Cancer Society projected about 35,780 new U.S. multiple myeloma cases in August 2024, including 19,520 in men and 16,260 in women, with an estimated 12,540 deaths. - Increased cancer research funding is also supporting market growth. - The National Cancer Institute allocated about $7.3 billion to cancer research in 2023, a 5.9% increase from the prior year. - Of that total, $407.6 million went to cancer research projects and clinical trials. - In 2025, North America held the largest share of the global Tecvayli market. - The report also covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspot infographics, key technology analysis and future trend analysis.

Between the lines: - The forecast suggests Tecvayli is benefiting from a broader shift toward precision oncology and newer immune-based treatments in hematologic cancers. - The emphasis on real-world evidence and patient monitoring signals a market that may be judged not only on efficacy, but also on how well it performs in routine care. - North America's lead suggests the region remains the early center of adoption for advanced oncology biologics, with other regions still building access.

What's next: - The market’s next phase likely depends on how quickly bispecific antibodies, BCMA-targeted approaches and combination regimens gain wider clinical use. - Expansion in emerging regions will hinge on access to advanced biologics and oncology infrastructure. - Ongoing cancer research spending and clinical trial activity are likely to keep shaping treatment development and market demand.